Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
accepted:
22
03
2021
pubmed:
30
4
2021
medline:
4
3
2022
entrez:
29
4
2021
Statut:
ppublish
Résumé
Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis. To report 52-week results from a prespecified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate-to-severe plaque psoriasis from the head-to-head EXCEED monotherapy study comparing secukinumab with adalimumab. Patients were randomized to receive secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48 or adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50. Assessments in patients with concomitant moderate-to-severe psoriasis, defined as having affected body surface area > 10% or Psoriasis Area and Severity Index (PASI) ≥ 10 at baseline, included musculoskeletal, skin and quality-of-life outcomes. Missing data were handled using multiple imputation. Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate-to-severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. The proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76·4% with secukinumab vs. 68·3% with adalimumab (P = 0·175), PASI 100 response was 39·1% vs. 23·8% (P = 0·013), and simultaneous improvement in ACR 50 and PASI 100 response at week 52 was 28·2% vs. 17·7%, respectively (P = 0·06). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints. This prespecified analysis in PsA patients with concomitant moderate-to-severe plaque psoriasis in the EXCEED study provides further evidence that IL-17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
Sections du résumé
BACKGROUND
Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis.
OBJECTIVES
To report 52-week results from a prespecified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate-to-severe plaque psoriasis from the head-to-head EXCEED monotherapy study comparing secukinumab with adalimumab.
METHODS
Patients were randomized to receive secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48 or adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50. Assessments in patients with concomitant moderate-to-severe psoriasis, defined as having affected body surface area > 10% or Psoriasis Area and Severity Index (PASI) ≥ 10 at baseline, included musculoskeletal, skin and quality-of-life outcomes. Missing data were handled using multiple imputation.
RESULTS
Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate-to-severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. The proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76·4% with secukinumab vs. 68·3% with adalimumab (P = 0·175), PASI 100 response was 39·1% vs. 23·8% (P = 0·013), and simultaneous improvement in ACR 50 and PASI 100 response at week 52 was 28·2% vs. 17·7%, respectively (P = 0·06). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints.
CONCLUSIONS
This prespecified analysis in PsA patients with concomitant moderate-to-severe plaque psoriasis in the EXCEED study provides further evidence that IL-17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
Identifiants
pubmed: 33913511
doi: 10.1111/bjd.20413
pmc: PMC9291158
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1124-1134Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Ann Rheum Dis. 2020 Jan;79(1):123-131
pubmed: 31563894
Dermatol Ther (Heidelb). 2018 Dec;8(4):571-579
pubmed: 30334147
Arthritis Rheum. 2005 Oct;52(10):3279-89
pubmed: 16200601
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699
pubmed: 28602039
Ann Rheum Dis. 2019 Sep;78(9):1215-1219
pubmed: 31113794
Scand J Rheumatol. 2019 Sep;48(5):375-382
pubmed: 31311386
Br J Dermatol. 2017 Sep;177(3):628-636
pubmed: 28513835
Am J Clin Dermatol. 2016 Feb;17(1):87-97
pubmed: 26718712
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Ther Adv Chronic Dis. 2015 Jul;6(4):194-203
pubmed: 26137209
Clin Rheumatol. 2014 May;33(5):609-14
pubmed: 24609758
Rheumatology (Oxford). 2015 May;54(5):915-26
pubmed: 25349441
Lancet. 2015 Sep 19;386(9999):1137-46
pubmed: 26135703
Drugs. 2014 Mar;74(4):423-41
pubmed: 24566842
J Am Acad Dermatol. 2015 Aug;73(2):242-8
pubmed: 26054432
J Rheumatol. 2016 Mar;43(3):632-9
pubmed: 26669916
J Dtsch Dermatol Ges. 2018 May;16(5):645-669
pubmed: 29750443
Lancet. 2020 May 9;395(10235):1496-1505
pubmed: 32386593
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Arthritis Res Ther. 2018 Mar 15;20(1):47
pubmed: 29544534
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
Rheumatology (Oxford). 2012 Aug;51(8):1368-77
pubmed: 22344575
J Rheumatol. 2020 Jun 1;47(6):847-853
pubmed: 31615918
RMD Open. 2018 Aug 13;4(2):e000723
pubmed: 30167329
Br J Dermatol. 2007 Nov;157(5):850-60
pubmed: 17725671
Exp Ther Med. 2020 Jul;20(1):47-51
pubmed: 32508992
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392